Literature DB >> 26126150

The Prospective External Validation of International Ovarian Tumor Analysis (IOTA) Simple Rules in the Hands of Level I and II Examiners.

A Knafel1, T Banas2, A Nocun2, M Wiechec2, R Jach2, A Ludwin3, M Kabzinska-Turek2, M Pietrus2, K Pitynski2.   

Abstract

Objective: To externally validate the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR) by examiners with different levels of sonographic experience defined by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) and to assess the morphological ultrasound features of the adnexal tumors classified as inconclusive based on IOTA SR. Materials and
Methods: In the two-year prospective study adnexal tumors were assessed preoperatively with transvaginal ultrasound by examiners with different levels of experience (level 1- IOTA SR1, level 2-IOTA SR2). Additionally, an expert (level 3) evaluated all tumors by subjective assessment (SA). If the rules could not be applied, the tumors were considered inconclusive. The final diagnosis was based on the histopathological result of the removed mass. The diagnostic performance measures for the assessed model were sensitivity, specificity, negative (LR-) and positive(LR+) likelihood ratios, accuracy (ACC) and diagnostic odds ratio (DOR).
Results: 226 women with adnexal tumors scheduled for surgery were included in the stutdy. The prevalence of malignancy was 36.3 % in the group of all studied tumors and was 52.5 % in the inconclusive group (n = 40) (p = 0.215). Fewer tumors were classified as inconclusive by level 2 examiners compared to level 1 examiners [20 (8.8 %) vs. 40 (17.7 %); p = 0.008], resulting from the discrepancy in the evaluation of acoustic shadows and the vascularization within the tumor. For level 1 examiners a diagnostic strategy using IOTA SR1 +MA (assuming malignancy when SR inconclusive) achieved a sensitivity, specificity and DOR of 96.3 %, 81.9 %, 13.624 respectively. For level 2 examiners the diagnostic strategy for IOTA SR2 +MA achieved a sensitivity, specificity and DOR of 95.1 %, 89.6 %, 137,143, respectively. Adding SA by an expert (or level 3 examiner) when IOTA SR were not applicable improved the specificity of the test and achieved a DOR of 505.137 (SR1 +SA) and 293.627 (SR2 +SA). The SA by an expert proved to have the best diagnostic performance with a DOR of 5768.857, and a sensitivity and specificity of 97.6 % and 99.3 % respectively. Within the inconclusive group the most common tumors were unilocular-solid (n-13), solid (n-8) and multilocular-solid (n-10) ones. All multilocular tumors were classified as inconclusive because of their size (≥ 100 mm) and were found to be benign by pathology. Most of the inconclusive tumors with cystic content presented low-level (43.75 %) echogenicity, followed by ground-glass (34.37 %), mixed (12.5 %) and anechoic (9.4 %).
Conclusion: The study results show excellent diagnostic performance of IOTA Simple Rules followed by subjective expert assessment in inconclusive tumors irrespective of the level of experience, while subjective assessment by an expert still has the highest diagnostic odds ratio. The number of inconclusive cases seems to depend on the level of ultrasound expertise and less experienced examiners have a tendency to overestimate blood flow and a presence of acoustic shadows within the tumors. IOTA SR were not applicable either because no benign or malignant features were found or both were identified. Within inconclusive tumors the majority of cases comprise malignant masses that are either unilocular-solid, solid tumors or small multilocular-solid ones with a diameter of less than 100 mm. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26126150     DOI: 10.1055/s-0034-1398773

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  6 in total

1.  Predictive accuracy and reproducibility of the O-RADS US scoring system among sonologists with different training levels.

Authors:  Manli Wu; Man Zhang; Junyan Cao; Shuangyu Wu; Ying Chen; Liping Luo; Xin Lin; Manting Su; Xinling Zhang
Journal:  Arch Gynecol Obstet       Date:  2022-08-22       Impact factor: 2.493

2.  Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population.

Authors:  Wouter Froyman; Laure Wynants; Chiara Landolfo; Tom Bourne; Lil Valentin; Antonia Testa; Povilas Sladkevicius; Dorella Franchi; Daniela Fischerova; Luca Savelli; Ben Van Calster; Dirk Timmerman
Journal:  Diagnostics (Basel)       Date:  2017-06-02

3.  Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems

Authors:  Artur Czekierdowski; Norbert Stachowicz; Agata Smoleń; Tomasz Kluz; Tomasz Łoziński; Andrzej Miturski; Janusz Kraczkowski
Journal:  Diagnostics (Basel)       Date:  2021-02-28

4.  Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules.

Authors:  Siew Fei Ngu; Yu Ka Chai; Ka Man Choi; Tsin Wah Leung; Justin Li; Gladys S T Kwok; Mandy M Y Chu; Ka Yu Tse; Vincent Y T Cheung; Hextan Y S Ngan; Karen K L Chan
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

Review 5.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

6.  Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.

Authors:  Núria Carreras-Dieguez; Ariel Glickman; Meritxell Munmany; Georgina Casanovas; Núria Agustí; Berta Díaz-Feijoo; Adela Saco; Beatriz Sánchez; Lydia Gaba; Martina Aida Angeles; Jaume Pahisa; Esther Fernández-Galán; Aureli Torné; Pere Fusté
Journal:  Diagnostics (Basel)       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.